Cell cloning and subsequent process development activities are on the critical path directly impacting the timeline for advancement of next generation therapies to patients with unmet medical needs. The use of stable cell pools for early stage material generation and process development activities is an enabling technology to reduce timelines. To successfully use stable pools during development, it is important that bioprocess performance and requisite product quality attributes be comparable to those observed from clonally derived cell lines. To better understand the relationship between pool and clone derived cell lines, we compared data across recent first in human (FIH) programs at Amgen including both mAb and Fc-fusion modalities. We compared expression and phenotypic stability, bioprocess performance, and product quality attributes between material derived from stable pools and clonally derived cells. Overall, our results indicated the feasibility of matching bioprocess performance and product quality attributes between stable pools and subsequently derived clones. These findings support the use of stable pools to accelerate the advancement of novel biologics to the clinic.
Introduction
The development and production of protein-based therapeutics relies on the ability to generate material with acceptable product quality to ensure patient safety and efficacy. 1 Many biologics rely on the use of mammalian cell-based production systems. 2 Typically, cells are genetically altered to express the gene of interest through the introduction of foreign DNA followed by a stringent selection step in which cells that incorporate the transgene have a survival advantage. [3] [4] [5] Despite this process typically relying on random integration of the DNA into the host cell genome, it has remained essentially unchanged, as it has been proven to be a robust approach to generate recombinant cell lines to support commercial biotherapeutic manufacturing.
During the initial clinical and commercial development of recombinant protein therapeutics in the 1980s, little was known about the important elements required to ensure a robust bioprocess and consistent product quality during material production. [6] [7] [8] This led to the development of various regulatory guidance documents [9] [10] [11] [12] and industrial publications 13 aiming to discuss best practices to develop recombinant cell lines. A common theme in these documents is guidance on the source of the cell substrate used for material generation. This has resulted in the requirement to use well characterized, clonally derived cell lines, whereby a transfected cell population is subjected to a process aimed at isolating a single cell from which a population is generated to create cell banks for future production. During a typical cell line development campaign, hundreds or even thousands of cell clones are screened to identify a suitable clonally derived cell line for future manufacturing needs. 14 The selection relies on a preliminary assessment of cell growth, expression level, and product quality. As the collective understanding of mammalian cell derived biologics manufacturing has matured over the last two decades, it is becoming increasingly evident that the nature of the cell substrate is one of multiple dimensions of a comprehensive control strategy required to ensure a successful pathway for clinical and commercial development. To this point, a number of recent studies have demonstrated the diversity of cell populations irrespective of the origin of the population, 13, [15] [16] [17] highlighting the need to focus on the quality of the product being manufactured and the robustness of the associated bioprocess.
Another important aspect of developing biologics is the need for accelerated patient access to novel therapies, especially in areas with critical unmet medical need. The path to generate a clonally derived cell line is laborious, time consuming, and is on the critical path for advancing a novel therapeutic to first in human (FIH) clinical trials. Consequently, approaches that accelerate this development step without affecting product quality and safety, are critical to accelerate patient access to novel therapies. Approaches using transient gene expression and transfected pools for therapeutic protein generation have been previously described, 18, 19 however, the work presented in this article and others in this issue also address both the comparability and acceleration strategy for subsequent clinical development. To achieve this outcome, we explored the use of stable pools as the cell substrate to generate early material used for toxicology and other non-clinical studies. This ensured that the subsequent time invested in generating the clonally derived cell line that was used to make material for human clinical studies was off critical path resulting in >5 month program acceleration. To ensure robustness of this two tier cell line generation strategy, we conducted comprehensive comparability analysis of the material derived from stable pools and clones from commercial-scale production campaigns for non-clinical and FIH clinical material generation. Specifically, cell line stability, upstream and downstream process performance, and product quality were rigorously characterized and compared. Overall, our data suggested that stable pools and cell clones produced comparable material and judicious use of cell substrates to supply material for non-clinical studies including toxicology and human clinical studies can significantly accelerate entry of novel biologics into FIH studies with no adverse impact to quality, efficacy, and safety.
Materials and Methods

Cell line development
Cell lines were generated by transfection of a proprietary CHO host cell line with plasmid DNA encoding molecule A (glycosylated human IgG1 antibody), molecule B (aglycosylated human IgG1 antibody), or molecule C (aglycosylated human IgG1 Fc-fusion protein). 20 Transfected cells were maintained by passaging under selective pressure until populations maintained consistent doubling times and high viability, following which frozen cell banks were created from the recovered pools. Clonally derived subclones were generated by depositing single cells from starting pools into microtiter plates by flow cytometry on a BD FACSAria TM II (BD, Franklin Lakes, NJ). Cells were scaled up to suspension culture, screened for desirable bioprocess and product attributes, and the top clones were banked.
Cell line stability study
Banks from stable pools and clones were cultured repeatedly by inoculation at a target seed density using cell concentration measurements from Vi-Cell XR cell viability analyzer (Beckman Coulter, Brea, CA). Additional intermediate banks were frozen at different population doublings. Selected intermediate banks representing research cell bank (RCB), master cell bank (MCB), start of production, and end of production were analyzed by performing a fed-batch experiment. Cultures were inoculated at a target cell density into a proprietary production media. Cultures were fed a single bolus feed and in-process samples were taken on fixed culture days. Cell count and viability were determined using a Vi-Cell XR cell viability analyzer (Beckman Coulter, Brea, CA). Product titers were measured by affinity POROS Protein A high performance liquid chromatography (HPLC) (Applied Biosystems, Carlsbad, CA) and aggregate levels were measured by size exclusion ultra-high performance liquid chromatography (SE-UHPLC).
Bioreactor cultivation
Cell banks from stable pools or subclones were thawed and scaled up by dilution and were passaged into increasing volumes of a proprietary chemically defined medium using shake flasks (Corning, Tewksbury, MA) and wave bioreactors (Thermo Scientific, Walham, MA) until an adequate cell number was reached to inoculate a manufacturing-scale bioreactor at 1 3 10 6 cells/mL. Bioreactor temperature and pH was controlled.
Viable cell density and viability were measured daily using a BioProfile CDV cell counter (Nova Biomedical, Waltham, MA) and product concentration was measured by affinity POROS Protein A HPLC (Applied Biosystems, Carlsbad, CA). Desired protein products were harvested and purified from the cell culture using Amgen's proprietary downstream platform processes. The same downstream process was used for both stable pools and clonally derived cell lines.
Cation exchange chromatography
Cation exchange chromatography (CEX) was used to determine the purity and distribution of charge variants using a cation exchange analytical column. Charge variants were eluted using a mobile phase gradient of increasing ionic strength under appropriate pH. Peaks corresponding to different eluted charge variants were detected by UV and integrated. The results for main, acidic, and basic peaks were reported as the percentage of the total peak area.
Size exclusion chromatography (SEC)
Ultra-high performance size exclusion liquid chromatography (SE-UHPLC) was utilized to separate proteins in solution based on their hydrodynamic volume. Components were eluted isocratically and monitored by UV detection at 280 nm. The resulting chromatogram was integrated and the results were reported as relative peak area percentages of high molecular weight (HMW), main (monomer), and low molecular weight (LMW) peaks.
Hydrophilic Interaction Liquid Chromatography
Hydrophilic interaction liquid chromatography (HILIC) was used for N-linked oligosaccharide profiling. This procedure involves releasing the N-linked oligosaccharides with PNGase F treatment, labeling the released carbohydrates with 2-aminobenzoic acid (2-AA), followed by HILIC separation using a Waters Acquity UPLC 1.7 lm BEH Glycan column. Eluted peaks were monitored with a fluorescence detector (excitation at 360 nm, emission at 425 nm). The N-linked glycan profile was determined as a percentage of the total integrated peak area.
Mass spectrometry-based: Multi-attribute method and sequence variance analysis For the multi-attribute method (MAM) analysis, proteins were denatured, reduced, alkylated, and then enzymatically digested. Digested fragments were separated by reversed phase chromatography with a gradient of water/acetonitrile with formic acid. Eluted peaks were detected by LC-MS using an ultra high performance liquid chromatography (UHPLC) system coupled to an Exactive Plus Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA). Mass spectrometry was utilized for quantification of individual attributes and this was done by a relative comparison of the peak areas from extracted ion chromatograms of the dominant isotopic peaks from multiple charge states between unmodified and modified peptides using commercially available Chromeleon software (Thermo Fisher Scientific, Waltham, MA). 21 MAM was also used to verify identity, and the test sample was assessed against the reference standard for retention time, mass accuracy, and peak area using molecule specific peptides. Sequence variant analysis was conducted as previously described. 22 Reduced capillary electrophoresis-sodium dodecyl sulfate
Reduced capillary electrophoresis-sodium dodecyl sulfate (rCE-SDS) separates proteins based on their hydrodynamic sizes under reducing and denaturing conditions. Proteins were denatured, reduced, and injected into bare fused silica capillary filled with a polymer gel matrix. Proteins were detected using a photodiode array (PDA) detector, integrated, and the results reported as relative peak area percentages.
Enzyme-linked immunosorbent assay identification
Product identity testing utilized an enzyme-linked immunosorbent assay (ELISA), where microtiter strips were coated with a molecule specific primary antibody. Samples or controls, a biotinylated secondary antibody, and neutravidinhorseradish peroxidase were added into the wells and allowed to incubate. Product present in the samples would bind to the immobilized primary antibodies and the biotinylated secondary antibody. Through the highly specific interaction of biotin with neutravidin-horseradish peroxidase, the extent of the reaction was measured by a chromogenic substrate to determine the identity of test substance in the sample. A quenching reagent was used to stop the color development and a microplate reader was used to measure absorbance. Identity was determined by calculating the signal-to-noise ratio between the optical absorbance of the sample compared to a blank.
Residual host cell DNA
The presence of residual host cell DNA impurity was detected and quantified using quantitative polymerase chain reaction technology (qPCR). Total DNA was isolated from the test sample and assay controls. Using qPCR, the residual host cell DNA was detected by amplifying a fragment of a repetitive sequence from the host cell genome. A gene specific-probe labeled with a reporter and a quencher, and specific primers designed to amplify the target DNA were present in qPCR reaction mixture along with the target DNA template. The amount of target DNA was determined by comparing the fluorescent intensity of the sample to a standard curve. A spike control containing a known amount of host cell DNA was used as a positive control. Results were reported in picograms of DNA per milligram of protein.
Protein A ELISA
A Protein A ELISA is an impurity method used to detect and quantify leached Protein A from the process into the product. Polystyrene 96-well microtiter plates were coated with a primary antibody that specifically captures recombinant Protein A in the samples. The concentration of recombinant Protein A in the samples was determined by interpolation from a calibration standard curve.
Host cell protein ELISA
Polystyrene 96-well microtiter plates were coated in-house with a primary antibody prepared by Amgen that specifically binds host cell protein (HCP). After the plate was washed and blocked, test samples, assay control, and HCP calibration standard were then added to the coated plate. Unbound proteins were washed from the plate and the captured HCP was detected with a pooled biotinylated secondary antibody, which in turn reacted with a streptavidin-horseradish peroxidase conjugate. The concentration of HCP in the samples was determined from the calibration standard curve and reported as nanograms HCP per milligram protein.
Potency
Potency was assessed either using a cell-based bioassay or direct antigen binding assay. The cell-based bioassay was designed to measure cell killing. In this assay, effector was incubated with target cells and molecule C (Fc-Fusion protein). Assessment of the ability of molecule C to engage and kill the target cells was made using a surrogate measure of cell number and viability. The direct antigen binding assay measured the ability of molecule B (human IgG1 mAb) to bind to its target receptor. In this assay, a fixed concentration of receptor was incubated with molecule B and assessed using a chemiluminescence readout. Cell bank from a stable pool showed comparable performance to a clonally derived cell bank over representative timelines required for large-scale manufacturing. (A) Cell banks from a pool and clonally isolated subclone were passaged to achieve population doubling levels (PDLs) representative of a manufacturing scale run up until the end of production. (B) Cells from various representative time points (research cell bank (RCB), master cell bank (MCB), start of production, and end of production) were analyzed for titer, peak viable cell density, high molecular weight species, a-fucosylated species, high mannose species, and galactosylation levels (A2G2F species). Data from latter time points were compared to the starting point (RCB) for stable pool (solid-square) and single clone (dotted-circle).
Results
Homogenous stable pools are achievable through a stringent cell line development platform
In order to assess the suitability of stable pools for use in material generation we examined the impact of selection stringency and cell line development strategy on the transfected cells. Figure 1 depicts two CHO cell line development platforms with varying vector systems and selection stringencies for the expression of a secreted monoclonal antibody. In both platforms, the CHO host cell line was transfected with either one or two vectors containing the heavy chain, light chain, and the gene for metabolic selection. Following transfection, the cells were grown in proprietary selective medium until recovery of stable pools. Evaluation of stable pool populations by flow cytometric analysis of surface human-Fc expression indicated that alternate selection strategies often contained a large population of non-expressing or lowexpressing cells (Figure 1, left panel) . Alternatively, when the pool selection process is optimized, the resulting pool can be more homogeneous with a majority of the population secreting the desired product (Figure 1, right panel) .
In order to compare homogeneity of stable pools with a clonally derived cell bank, the pools were single cell subcloned using fluorescent-activated cell sorting (FACS) to isolate single cells. These single cells were expanded and screened for desirable manufacturing properties. When analyzed for surface human-Fc expression, the histogram profile was comparable to the stable pools ( Figure 1, right panel) .
Stable pools exhibit comparable stability to clonally derived cell lines over timelines representative of large-scale manufacturing activities
To determine protein expression stability of stringently selected pools over the duration of cell banking and large-scale manufacturing, a stability study was performed on both stable pools and clonally derived cell banks. As shown in Figure 2A , a stable pool and the final single clone for molecule A (mAb) were characterized over 35 population doubling levels (PDLs) to span the duration from RCB and MCB creation, scale up, and to large-scale manufacturing. Selected time points across these activities were analyzed and secreted antibody product was characterized. It is evident from Figure 2B that the stable pool achieved comparable stability with respect to cell growth, protein expression, and multiple product quality attributes including HMW species, afucosylation, high mannose species, and galactosylation over this long duration. These observations demonstrate the suitability of stable pools to provide material for non-clinical studies that would be comparable to subsequent clinical material generated from clonally derived cells.
Manufacturing-scale bioprocess performance is comparable between stable pools and single clones
Based on the characterization data described in previous sections, a strategy for generation of non-clinical material from stable pools was applied. This enables early development activities to occur in parallel while clonally derived cells are isolated and selected off critical path enabling overall program acceleration to clinical studies. The final clone for clinical material manufacturing can then be selected based on similarity to early non-clinical material. This approach was applied to two molecules, molecule B (monoclonal antibody) and molecule C (Fc-fusion protein). Figure  3 shows bioprocess performance for both molecules and compares the non-clinical material manufacturing run using stable pools versus the clinical run which used a clonally derived cell bank. Cell growth, viability, and product titer were similar across both runs for both molecules and there were no significant differences in the downstream unit operation yields, impurity removal, or other inprocess parameters. Overall, similar bioprocess performance was observed between the two manufacturing scale runs. Manufacturing-scale materials from stable pools and single clones show comparable product quality and stability profiles Drug substance generated from the non-clinical run (using stable pool) and the clinical campaigns (using clonally derived cell line) were characterized for identity, purity, impurity, and potency attributes as listed in Tables 1 and 2 . For molecule B (mAb), the identities of both non-clinical and clinical materials were confirmed by two complimentary approaches, ELISA and MAM (Table 1 ). Both materials were highly similar regarding size (99.6%-99.7% main peak and 0.3%-0.4% HMW species) and charge distribution (73.7%-74.2% main peak, 7.9%-10.5% acidic peak, and 15.8%-17.9% basic peak) with <1% total sequence variance. Selected critical quality attributes (e.g. deamidation or oxidation) were compared using MAM and also assessed for potential changes in the primary structure and/or posttranslational modifications. Results met comparability criteria across the two cell substrates.
Typical impurities such as host cell DNA, HCP, and Protein A leached from downstream purification were equally low (<0.2 pg/mg, 2 ng/mg, and 7 ng/mg, respectively). The relative potency of both materials was comparable to the reference standard (102% and 97%, respectively).
Similar comparability between non-clinical and clinical materials was also observed for molecule C (Fc-fusion protein). As listed in Table 2 , both materials passed identify verification assays (ELISA and MAM). The size distribution (99.4%-99.5% main peak and 0.3% HMW) and the charge distribution (87.2%-92.3% main peak, 2.9%-3.1% acidic peak, and 4.6%-10.0% basic peak) were highly similar. A decrease in the % Main Peak detected by CEX was observed for clinical material compared to the non-clinical material. The decrease correlates with a relative increase in the % Basic Peak. Further analytical characterization suggests that the increase in the basic peak is the result of additional Cterminal lysine. 23 Both materials were similar when typical impurities were analyzed (<1.9 pg/mg host cell DNA, 11 ng/mg HCP, and <1 ng/mg leached Protein A). Compared to the reference standard, both materials exhibited similar relative potency (128% for non-clinical material and 105% for clinical material).
Discussion
The use of transfected cell pools during early development offers significant acceleration for advancing promising novel therapeutics to patients with unmet medical need. Key nonclinical activities are enabled months earlier, removing them from the critical path for advancement toward FIH clinical safety and proof of concept studies. The successful implementation of this approach relies on an in-depth understanding of the expression system being used as well as the bioprocess and analytical platforms to generate and characterize the material irrespective of the cell substrate source. In addition, recent advancements in the resolution of analytical methods based on mass spectrometry allow interrogation at an amino acid residue specific level as well as addressing issues such as micro-heterogeneity or sequence variants at levels below that observed in naturally derived proteins. 21, 22 The optimized pool generation process employed here was shown to maintain long-term stability, acceptable bioprocess performances, as well as consistent product quality at both laboratory-and manufacturing-scales and across molecule types. Collectively, these data clearly demonstrate the suitability of stable pools for material generation to support early development and accelerate patient access to novel biotherapeutics.
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